IGMS vs. ABUS, AVTE, YMAB, APLT, ALT, KALV, SIGA, CMPS, VERV, and ATXS
Should you be buying IGM Biosciences stock or one of its competitors? The main competitors of IGM Biosciences include Arbutus Biopharma (ABUS), Aerovate Therapeutics (AVTE), Y-mAbs Therapeutics (YMAB), Applied Therapeutics (APLT), Altimmune (ALT), KalVista Pharmaceuticals (KALV), SIGA Technologies (SIGA), COMPASS Pathways (CMPS), Verve Therapeutics (VERV), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical preparations" industry.
Arbutus Biopharma (NASDAQ:ABUS) and IGM Biosciences (NASDAQ:IGMS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.
Arbutus Biopharma has higher revenue and earnings than IGM Biosciences. Arbutus Biopharma is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.
Arbutus Biopharma has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500.
43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 42.8% of IGM Biosciences shares are held by institutional investors. 4.0% of Arbutus Biopharma shares are held by company insiders. Comparatively, 56.9% of IGM Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, IGM Biosciences had 2 more articles in the media than Arbutus Biopharma. MarketBeat recorded 7 mentions for IGM Biosciences and 5 mentions for Arbutus Biopharma. IGM Biosciences' average media sentiment score of 1.05 beat Arbutus Biopharma's score of 0.69 indicating that Arbutus Biopharma is being referred to more favorably in the media.
Arbutus Biopharma has a net margin of -572.81% compared to Arbutus Biopharma's net margin of -11,255.25%. IGM Biosciences' return on equity of -62.68% beat Arbutus Biopharma's return on equity.
Arbutus Biopharma presently has a consensus target price of $4.33, indicating a potential upside of 49.94%. IGM Biosciences has a consensus target price of $17.89, indicating a potential upside of 92.56%. Given Arbutus Biopharma's higher probable upside, analysts clearly believe IGM Biosciences is more favorable than Arbutus Biopharma.
Arbutus Biopharma received 362 more outperform votes than IGM Biosciences when rated by MarketBeat users. Likewise, 70.83% of users gave Arbutus Biopharma an outperform vote while only 49.22% of users gave IGM Biosciences an outperform vote.
Summary
Arbutus Biopharma beats IGM Biosciences on 12 of the 18 factors compared between the two stocks.
Get IGM Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IGMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IGM Biosciences Competitors List
Related Companies and Tools
